Compounders Research Compare

NRx Pharmaceuticals, Inc.(NRXP)

Biotechnology · Wilmington, DE

$2.97+0.09 (+3.31%)

Delayed quote: Oct 6, 2026, 2:54 PM EDT

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Wilmington, DE

29 employees

www.nrxpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jonathan C. Javitt

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T18:57:56.928Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:57:56.928Z.

Quote observation: 2026-10-06T18:54:55.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 128,371,949
TTM free cash flow · period ending 2026-06-30: -20,671,000

FMP input reference: 7a446221ee70341de49d615c46e15f9be625c30a72cedc9ff9e6473dbc59ae23

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NRXP Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

NRXP Competitors' Price/FCF Ratio

NRx Pharmaceuticals, Inc.

Current

Market Cap

$128.37M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pyxis Oncology, Inc.

Market Cap

$129.76M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Entera Bio Ltd.

Market Cap

$127.42M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Tonix Pharmaceuticals Holding Corp.

Market Cap

$124.98M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AirSculpt Technologies, Inc.

Market Cap

$133.33M

Price/FCF Ratio

175.44

TTM Avg

111.34

3Y Avg

100.72

5Y Avg

72.71

Health Catalyst, Inc.

Market Cap

$133.01M

Price/FCF Ratio

10.18

TTM Avg

13.06

3Y Avg

13.06

5Y Avg

13.06

TuHURA Biosciences, Inc.

Market Cap

$123.54M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeMD, Inc.

Market Cap

$133.48M

Price/FCF Ratio

N/A

TTM Avg

63.37

3Y Avg

576.34

5Y Avg

569.67

Cibus, Inc.

Market Cap

$122.13M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Seer, Inc.

Market Cap

$121.23M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
NRx Pharmaceuticals, Inc. (NRXP)	$128.37M	N/A	N/A	N/A	N/A
Pyxis Oncology, Inc. (PYXS)vs ›	$129.76M	N/A	N/A	N/A	N/A
Entera Bio Ltd. (ENTX)vs ›	$127.42M	N/A	N/A	N/A	N/A
Tonix Pharmaceuticals Holding Corp. (TNXP)vs ›	$124.98M	N/A	N/A	N/A	N/A
AirSculpt Technologies, Inc. (AIRS)vs ›	$133.33M	175.44	111.34	100.72	72.71
Health Catalyst, Inc. (HCAT)vs ›	$133.01M	10.18	13.06	13.06	13.06
TuHURA Biosciences, Inc. (HURA)vs ›	$123.54M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMD)vs ›	$133.48M	N/A	63.37	576.34	569.67
Cibus, Inc. (CBUS)vs ›	$122.13M	N/A	N/A	N/A	N/A
Seer, Inc. (SEER)vs ›	$121.23M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics